|Bid||169.69 x 1300|
|Ask||250.00 x 800|
|Day's Range||176.50 - 192.61|
|52 Week Range||66.01 - 249.42|
|Beta (5Y Monthly)||1.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021 - May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||247.91|
In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a late-stage targeted oncology company, will participate in two upcoming healthcare conferences.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.